Skip to Content
Morningstar

Exelixis Inc EXEL

Morningstar Rating
Unlock
Stock XNAS Rating as of
$21.90 −0.22 (0.99%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Exelixis Earnings: Cabozantinib Drives Sales, but Patent Expirations Present Challenges

Rachel Elfman

Exelixis started 2024 in a solid position with total revenue of $425 million in the first quarter, a 4% increase from the prior-year period. We forecast 2024 total revenue of roughly $1.89 billion, driven by strong performance from cabozantinib. The results are in line with our expectations, and we maintain our $18.90 fair value estimate. We view the shares as currently overvalued, trading at a 17% premium to our fair value estimate.

Read Full Report

Price vs Fair Value

View History
EXEL is trading at a 16% premium.
Price
$21.90
Fair Value
$33.80
Uncertainty
High
1-Star Price
$77.30
5-Star Price
$69.52
Economic Moat
Blzr
Capital Allocation
Ccyqczydb

Bulls Say, Bears Say

Bulls

Cabozantinib has been effective in a variety of cancers, including kidney, liver, and thyroid cancers, and label expansions could further expand the drug’s market opportunity.

Bears

Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest U.S. patent covering cabozantinib’s composition of matter expires in 2026.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EXEL is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$22.12
Day Range
$21.73–22.47
52-Week Range
$18.52–24.34
Bid/Ask
$19.50 / $23.50
Market Cap
$6.38 Bil
Volume/Avg
2.5 Mil / 2.4 Mil

Key Statistics

Price/Earnings (Normalized)
22.00
Price/Sales
3.75
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
8.63%

Company Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
1,310
Website
https://www.exelixis.com

Competitors

Valuation

View More
Metric
EXEL
UCB
JAZZ
Price/Earnings (Normalized)
 22.0025.906.45
Price/Book Value
 3.042.551.88
Price/Sales
 3.754.481.98
Price/Cash Flow
 20.2225.676.32
Price/Earnings
EXEL
UCB
JAZZ

Financial Strength

Metric
EXEL
UCB
JAZZ
Quick Ratio
 3.230.841.62
Current Ratio
 3.461.322.27
Interest Coverage
 —3.881.86
Quick Ratio
EXEL
UCB
JAZZ

Profitability

Metric
EXEL
UCB
JAZZ
Return on Assets (Normalized)
 9.61%5.10%11.13%
Return on Equity (Normalized)
 12.20%8.82%35.21%
Return on Invested Capital (Normalized)
 8.59%7.41%16.02%
Return on Assets
EXEL
UCB
JAZZ
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRXhcwrqyddDddl$545.9 Bil
REGN
Regeneron Pharmaceuticals IncDjxtwybrGdrjwp$105.4 Bil
VRTX
Vertex Pharmaceuticals IncRcsjvdmgHcgxm$103.7 Bil
MRNA
Moderna IncMpsqdsvplYhf$47.9 Bil
ARGX
argenx SE ADRTllxfpybPhkp$22.9 Bil
BNTX
BioNTech SE ADRQypsnyvjZny$22.3 Bil
ALNY
Alnylam Pharmaceuticals IncKtdzzypyHqjvvnr$19.3 Bil
BMRN
Biomarin Pharmaceutical IncJqzszxjcjSgwkx$15.7 Bil
RPRX
Royalty Pharma PLC Class AKtzlmtrygJtdlb$12.8 Bil
INCY
Incyte CorpYnbbtnyxZffjqy$12.1 Bil

Sponsor Center